title: Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.
abstract: The aims of this study are to investigate the frequency of derivative chromosome 9 (der (9)) deletion in Tunisian patients with chronic myeloid leukemia (CML) and to assess the correlation between this deletion and the cytogenetic response for patients treated with hydroxyurea (HU) or imatinib (IM). Karyotype analysis of 336 patients with CML was performed with R-banding technique. Fluorescence in situ hybridization (FISH) was carried using home-brew probes 17L7 and 248J22 for detecting, respectively, adjacent 5'ABL and 3'BCR deletions on der(9). Cytogenetic study demonstrated typical t(9;22)(q34;q11) translocation in 89.6% and variant translocation in 10.4% of patients. Interphase FISH studies showed deletion of der(9) in 59 (17.6%) of the 336 patients, 23 (39%) of them had variant rearrangements. There are 19 patients with solely 5'ABL deletion and 40 with concomitant 5'ABL and 3'BCR deletions. Cytogenetic response was evaluated during 18 months with HU or IM therapy. Our results demonstrate that (a) 3'BCR deletion is associated with 5'ABL deletion in all patients with der(9) deletions, (b) the 5'ABL and 3'BCR deletions arise simultaneously with t(9;22), (c) deletions on der(9) chromosome were frequently encountered in older patients and in patients presenting variant rearrangements, (d) both 5'ABL and 3'BCR deletions were associated with cytogenetic response failure in patients treated with HU, however, patients treated with IM and carrying der(9) deletions presented better cytogenetic response.
authors.affiliation: Department of Cytogenetics, Molecular Genetics and Reproductive Biology, Farhat Hached University Teaching Hospital, Sousse, Tunisia. aydabennour@yahoo.fr
authors.forename: Ayda
authors.initials: A
authors.lastname: Bennour
authors.forename: Ines
authors.initials: I
authors.lastname: Ouahchi
authors.forename: Yosra
authors.initials: Y
authors.lastname: Ben Youssef
authors.forename: Monia
authors.initials: M
authors.lastname: Zaier
authors.forename: Mohamed Adnéne
authors.initials: MA
authors.lastname: Laatiri
authors.forename: Imed
authors.initials: I
authors.lastname: Harrabi
authors.forename: Balkis
authors.initials: B
authors.lastname: Meddeb
authors.forename: Moez
authors.initials: M
authors.lastname: Elloumi
authors.forename: Abderrahim
authors.initials: A
authors.lastname: Khelif
authors.forename: Ali
authors.initials: A
authors.lastname: Saad
authors.forename: Halima
authors.initials: H
authors.lastname: Sennana
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D002872:Chromosome Deletion; D002892:Chromosomes, Human, Pair 22 / Q000235:genetics*; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics*; D015342:DNA Probes; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage; D011379:Prognosis; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics; D051562:Proto-Oncogene Proteins c-bcr / Q000235:genetics; D011743:Pyrimidines / Q000008:administration & dosage; D012189:Retrospective Studies; D014178:Translocation, Genetic / Q000235:genetics
chemical_list: D001549:Benzamides; D015342:DNA Probes; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016315:Proto-Oncogene Proteins c-abl; C496613:BCR protein, human; D051562:Proto-Oncogene Proteins c-bcr; D006918:Hydroxyurea